Tumor-suppressor p53: Implications for tumor development and prognosis

Journal of Clinical Oncology

Volumn 16, Issue 9, 1998, Pages 3158-3168

  Kirsch, David G ^a   Kastan, Michael B ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ARTICLE; CANCER RESEARCH; CANCER SURVIVAL; CARCINOGENESIS; CELL CYCLE; CELL GROWTH; COLORECTAL CANCER; GENE MUTATION; GENETIC STABILITY; HUMAN; PRIORITY JOURNAL; PROGNOSIS; SQUAMOUS CELL CARCINOMA;

EID: 0031717905     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.9.3158     Document Type: Article

References (129)

1. Lane DP, Crawford LV: T antigen is bound to host protein in SV40 transformed cells. Nature 278:261-263, 1979
2. Linzer DI, Levine AJ: Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell 17:43-52, 1979
3. Eliyahu D, Michalovitz D, Eliyahu S, et al: Wild-type p53 can inhibit oncogene-mediated focus formation. Proc Natl Acad Sci USA 86:8763-8767, 1989
4. Finlay CA, Hinds PW, Levine AJ: The p53 proto-oncogene can act as a suppressor of transformation. Cell 57:1083-1093, 1989
5. Baker SJ, Markowitz S, Fearon ER, et al: Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 249:912-915, 1990
6. Chen PL, Chen YM, Bookstein R, et al: Genetic mechanisms of tumor suppression by the human p53 gene. Science 250:1576-1580, 1990
7. Harris CC, Hollstein M: Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 329:1318-1327, 1993
8. Kastan MB, Onyekwere O, Sidransky D, et al: Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51:6304-6311, 1991
9. Jacobson MD, Weil M, Raff MC: Programmed cell death in animal development. Cell 88:347-354, 1997
10. Sherr CJ: Cancer cell cycles. Science 274:1672-1677, 1996
11. Chilosi M, Doglioni C, Magalini A, et al: p21/WAF1 cyclin-kinase inhibitor expression in non-Hodgkin's lymphomas: A potential marker of p53 tumor-suppressor gene function. Blood 88:4012-4020, 1996
12. Greenblatt MS, Bennett WP, Hollstein M, et al: Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res 54:4855-4878, 1994
13. Vogelstein B, Kinzler KW: p53 function and dysfunction. Cell 70:523-526, 1992
14. Graeber TG, Peterson JF, Tsai M, et al: Hypoxia induces accumulation of p53 protein, but activation of a g1-phase checkpoint by low-oxygen conditions is independent of p53 status. Mol Cell Biol 14:6264-6277, 1994
15. Serrano M, Lin AW, McCurrach ME, et al: Oncogenic ras provides premature cell senescence associated with accumulation of p53 and p16 INK4a. Cell 88:593-602, 1997
16. Maltzman W, Czyzyk L: UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells. Mol Cell Biol 4:1689-1694, 1984
17. Levine AJ: p53, the cellular gatekeeper for growth and division. Cell 88:323-331, 1997
18. Hupp TR, Meek DW, Midgley CA, et al: Regulation of the specific DNA binding function of p53. Cell 71:875-886, 1992
19. Shieh S-Y, Ikeda M, Taya Y, et al: DNA damage-induced phosphorylation of p53 alleviates inhibition by mdm2. Cell 91:325-334, 1997
20. Takenaka I, Morin F, Seizinger BR, et al: Regulation of the sequence-specific DNA binding function of p53 by protein kinase C and protein phosphatases. J Biol Chem 270:5405-5411, 1995
21. Gu W, Roeder RG: Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90:595-606, 1997
22. El-Deiry WS, Tokino T, Velculescu VE, et al: WAF1, a potential mediator of p53 tumor suppression. Cell 75:817-825, 1993
23. Nasmyth K: Viewpoint: Putting the cell cycle in order. Science 274:1643-45, 1996
24. Harper JW, Adami GR, Wei N, et al: The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75:805-816, 1993
25. Hartwell LH, Weinen TA: Checkpoints: Controls that ensure the order of cell cycle events. Science 246:629-634, 1989
26. Hartwell LH, Kastan MB: Cell cycle control and cancer. Science 266:1821-1828, 1994
27. Deng C, Zhang P, Harper JW, et al: Mice Lacking p21 CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 82:675-684, 1995
28. Brugarolas J, Chandrasekaran C, Gordon JI, et al: Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature 377:552-557, 1995
29. 1 arrest in human cancer cells. Cancer Res 55:5187-5190, 1995
30. Waldman T, Lengauer C, Kinzler KW, et al: Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature 381:713-716, 1996
31. Hermeking H, Lengauer C, Polyak K, et al: 14-3-3σ is a p53-regulated inhibitor of G2/M progression. Mol Cell 1:3-11, 1997
32. 2 checkpoint control: Regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216. Science 277:1501-1505, 1997
33. Kerr JFR, Wyllie AH, Currie AR: Apoptosis: A basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 26:239-257, 1972
34. Salvesen GS, Dixit VM: Caspases: Intracellular signaling by proteolysis. Cell 91:443-446, 1997
35. Miyashita T, Reed JC: Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80:293-299, 1995
36. Antonsson B, Conti F, Ciavatta AM, et al: Inhibition of Bax channel-forming activity by Bcl-2. Science 277:370-372, 1997
37. Rosse T, Olivier R, Monney L, et al: Bcl-2 prolongs cell survival after Bax-induced release of cytochrome c. Nature 391:496-499, 1998
38. Liu X, Kim CN, Yang J, et al: Induction of apoptotic program in cell-free extracts: Requirement for dATP and cytochrome c. Cell 86:147-157, 1996
39. Zhivotovsky B, Orrenius S, Brustugun OT, et al: Injected cytochrome c induces apoptosis. Nature 391:449-450, 1998
40. Wu GS, Burns TF, McDonald ER, III, et al: KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat Genet 17:141-143, 1997
41. Kastan MB: On the TRAIL from p53 to apoptosis? Nat Genet 17:130-131, 1997
42. Owen-Schaub LB, Zhang W, Cusack JC, et al: Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Mol Cell Biol 15:3032-3040, 1995
43. Sheridan JP, Marsters SA, Pitti RM, et al: Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277:818-821, 1997
44. Pan G, Ni J, Wei Y-F, et al: An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 277:815-818, 1997
45. Nagata S: Apoptosis by death factor. Cell 88:355-365, 1997
46. Buckbinder L, Talbott R, Velasco-Miguel S, et al: Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 377:646-649, 1995
47. Israeli D, Tessler E, Haupt Y, et al: A novel p53-inducible gene, PAG608, encodes a nuclear zinc finger protein whose overexpression promotes apoptosis. EMBOJ 16:4384-4392, 1997
48. Polyak K, Xia Y, Zweier JL, et al: A model for p53-induced apoptosis. Nature 389:300-305, 1997
49. Lowe SW, Bodis S, McClatchey A, et al: p53 status and the efficacy of cancer therapy in vivo. Science 266:807-810, 1994
50. Yoshida K, Murohashi I, Hirashima K: p53-independent induction of p21 (WAF1/CIP1) during differentiation of HL-60 cells by tumor necrosis factor alpha. Int J Hematol 65:41-48, 1996
51. Fuchs EJ, McKenna KA, Bedi A: p53-dependent DNA damage-induced apoptosis requires Fas/APO-1-independent activation of CPP32β. Cancer Res 57:2550-2554, 1997
52. Lowe SW, Schmitt SW, Smith SW, et al: p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362:847-849, 1993
53. Clarke AR, Purdie CA, Harrison DJ, et al: Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362:849-852, 1993
54. Santana P, Pena LA, Haimovitz-Friedman A, et al: Acid sphingomyelinase-deficient human lymphoblasts and mice are defective in radiation-induced apoptosis. Cell 86:189-199, 1996
55. Slichenmeyer WJ, Nelson WG, Slebos RJ, et al: Loss of a p53-associated G1 checkpoint does not decrease cell survival following DNA damage. Cancer Res 53:4164-4168, 1993
56. Leonard CJ, Canman CE, Kastan MB: The role of p53 in cell-cycle control and apoptosis: Implications for cancer, in DeVita VT, Hellman S, Rosenbert SA (eds): Important Advances in Oncology. Philadelphia, PA, Lippincott, 1995, pp 33-42
57. Canman CE, Gilmer T, Coutts S, et al: Growth factor modulation of p53-mediated growth arrest vs. apoptosis. Genes Dev 9:600-611, 1995
58. Lowe SW, Ruley HE, Jacks T, et al: p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74:957-967, 1993
59. Hawkins DS, Demers GW, Galloway DA: Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res 56:892-898, 1996
60. Livingstone LR, White A, Sprouse J, et al: Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 70:923-935, 1992
61. Yin Y, Tainsky MA, Bischoff FZ, et al: Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant P53 alleles. Cell 70:937-948, 1992
62. Harvey M, Sands AT, Weiss RS, et al: In vitro growth characteristics of embryo fibroblasts isolated from p53-deficient mice. Oncogene 8:2457-2467, 1993
63. Carder P, Wyllie AH, Purdie CA, et al: Stabilized p53 facilitates aneuploid clonal divergence in colorectal cancer. Oncogene 8:1397-1401, 1993
64. Fukasawa K, Choi T, Kuriyama R, et al: Abnormal centrosome amplification in the absence of p53. Science 271:1744-1747, 1996
65. Fearon ER, Vogelstein B: A genetic model for colorectal tumorigenesis. Cell 61:759-767, 1990
66. Ziegler A, Jonason AS, Leffell DJ, et al: Sunburn and p53 in the onset of skin cancer. Nature 372:773-776, 1994
67. Sozzi G, Miozzo M, Donghi R, et al: Deletions of 17p and p53 mutations in preneoplastic lesions of the lung. Cancer Res 52:6079-6082, 1992
68. Boyle JO, Hakim J, Koch W, et al: The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res 53:4477-4480, 1993
69. Baker SJ, Fearon ER, Nigro JM, et al: Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 244:217-221, 1989.
70. Donghi R, Longoni A, Pilotti S, et al: Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. J Clin Invest 91:1753-1760, 1993
71. Hollstein M, Sidransky D, Vogelstein B, et al: p53 mutations in human cancers. Science 253:49-53, 1991
72. Graeber TG, Osmanian C, Jacks T, et al: Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379:88-91, 1996
73. Ford JM, Hanawalt PC: Li-Fraumeni syndrome fibroblasts homozygous for p53 mutations are deficient in global DNA repair but exhibit normal transcription-coupled repair and enhanced uv resistance. Proc Natl Acad Sci USA 92:8876-8880, 1995
74. Bennett WP, Colby TV, Travis WD, et al: p53 protein accumulates frequently in early bronchial neoplasia. Cancer Res 53:4817-4822, 1993
75. Mao L, Hruban RH, Boyle JO, et al: Detection of oncogene mutations in sputum precedes diagnosis of lung cancer. Cancer Res 54:1634-1637, 1994
76. Denissenko MF, Pao A, Tang M, et al: Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in p53. Science 274:430-432, 1996
77. Ruggeri B, DiRado M, Zhang SY, et al: Benzo[a]pyrene-induced murine skin tumors exhibit frequent and characteristic G to T mutations in the p53 gene. Proc Natl Acad Sci USA 90:1013-1017, 1993
78. Boland CR, Sato J, Appelman HD, et al: Microallelotyping defines the sequence and tempo of allelic losses at tumour suppressor gene loci during colorectal cancer progression. Nat Med 1:902-909, 1995
79. zur Hausen H: Viruses in human cancers. Science 354:1167-1173, 1991
80. Scheffner M, Werness BA, Huibregtse JM, et al: The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63:1129-1136, 1990
81. Oliner JD, Kinzler KW, Meltzer P, et al: Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358:80-83, 1992
82. Momand J, Zambetti GP, Olson DC, et al: The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69:1237-1245, 1992
83. Barak Y, Juven T, Haffner R, et al: mdm2 expression is induced by wild type p53 activity. EMBO J 12:461-468, 1993
84. Guillou L, Estreicher A, Chaubert P, et al: Germ cell tumors of the testis overexpress wild-type p53. Am J Pathol 149:1221-1228, 1996
85. Peng H-Q, Hogg D, Malkin D, et al: Mutations of the p53 gene do not occur in testis cancer. Cancer Res 53:3574-3578, 1993
86. Vogan K, Bernstein M, Leclerc JM, et al: Absence of p53 gene mutations in primary neuroblastomas. Cancer Res 53:5269-5273, 1993
87. Kaghad M, Bonnet H, Yang a, et al: Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 90:809-819, 1997
88. Jost CA, Marin MC, Kaelin WG Jr: p73 is a human p53-related protein that can induce apoptosis. Nature 389:191-194, 1997
89. Malkin D, Li FP, Strong LC, et al: Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250:1233-1238, 1990
90. Srivastava S, Zou ZQ, Pirollo K, et al: Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature 348:747-749, 1990
91. Malkin D, Jolly KW, Barbier N, et al: Germline mutations of the p53 tumor-suppressor gene in children and young adults with second malignant neoplasms. N Engl J Med 326:1309-1315, 1992
92. Hall PA, Lane DP: p53 in tumour pathology: Can we trust immunohistochemistry? J Pathol 172:1-4, 1994
93. Ono Y, Tamiya T, Ichikawa T, et al: Accumulation of wild-type p53 in astrocytomas is associated with increased p21 expression. Acta Neuropathol 94:21-27, 1997
94. Bukholm IK, Nesland JM, Karesen R, et al: Relationship between abnormal p53 protein and failure to express p21 protein in human breast carcinomas. J Pathol 181:140-145, 1997
95. Moskaluk CA, Heitmiller R, Zahurak M, et al: p53 and p21(WAF1/CIP1/SDI1) gene products in Barrett esophagus and adenocarcinoma of the esophagus and esophagogastric junction. Hum Pathol 27:1211-1220, 1996
96. Zedenius J, Larsson C, Wallin G, et al: Alterations of p53 and expression of WAF1/p21 in human thyroid tumors. Thyroid 6:1-9, 1996
97. Wattel E, Preudhomme C, Hecquet B, et al: p53 Mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 84:3148-3157, 1994
98. Imamura J, Miyoshi I, Koeffler HP: p53 in hematologic malignancies. Blood 84:2412-2421, 1994
99. Ichikawa A, Kinoshita T, Watanabe T, et al: Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma. N Engl J Med 337:529-534, 1997
100. Nakai H, Misawa S, Taniwaki M, et al: Prognostic significance of loss of a chromosome 17p and p53 gene mutations in blast crisis of chronic myelogenous leukaemia. Br J Haematol 87:425-427, 1994
101. Diccianni MB, Yu J, Hsiao M, et al: Clinical significance of p53 mutations in relapsed T-cell acute lymphoblastic leukemia. Blood 84:3105-3112, 1994
102. Preudhomme C, Dervite I, Wattel E, et al: Clinical significance of p53 mutations in newly diagnosed Burkitt's lymphoma and acute lymphoblastic leukemia: A report of 48 cases. J Clin Oncol 13:812-820, 1995
103. Malkin D, Sexsmith E, Yeger H, et al: Mutations of the p53 tumor suppressor gene occur infrequently in Wilms' tumor. Cancer Res 54:2077-2079, 1994
104. Bardeesy N, Falkoff D, Petruzzi M, et al: Anaplastic Wilms' tumour, a subtype displaying poor prognosis, harbours p53 gene mutations. Nat Genet 7:91-97, 1994
105. Bardeesy N, Beckwith JB, Pelletier J: Clonal expansion and attenuated apoptosis in Wilms' tumors are associated with p53 gene mutations. Cancer Res 55:215-219, 1995
106. Kovach JS, Hartmann A, Blaszyk H, et al: Mutation detection by highly sensitive methods indicates that p53 gene mutations in breast cancer can have important prognostic value. Proc Natl Acad Sci USA 93:1093-1096, 1996
107. Bergh J, Norberg T, Sjogren S, et al: Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat Med 1:1029-1034, 1995
108. Liu E, Thor A, He M, et al: The HER2(c-erbB-2) oncogene is frequently amplified in in situ carcinomas of the breast. Oncogene 7:1027-1032, 1992
109. Baselga J, Mendelsohn J: The epidermal growth factor receptor as a target for therapy in breast carcinoma. Breast Cancer Res Treat 29:127-138, 1994
110. Jansson T, Inganas M, Sjogren S, et al: p53 status predicts survival in breast cancer patients treated with or without postoperative radiotherapy: A novel hypothesis based on clinical findings. J Clin Oncol 13:2745-2751, 1995
111. Friedlander P, Haupt Y, Prives C, et al: A mutant p53 that discriminates between p53-responsive genes cannot induce apoptosis. Mol Cell Biol 16:4961-4971, 1996
112. Aas T, Borresen AL, Geisler S, et al: Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 2:811-814, 1996
113. Hamelin R, Laurent-Puig P, Olschwang S, et al: Association of p53 mutations with short survival in colorectal cancer. Gastroenterology 106:42-48, 1994
114. Goh H-S, Yao J, Smith DR: p53 point mutation and survival in colorectal cancer patients. Cancer Res 55:5217-5221, 1995
115. Soong R, Grieu F, Robbins P, et al: p53 alterations are associated with improved prognosis in distal colonic carcinomas. Clin Cancer Res 3:1405-1411, 1997
116. Sidransky D: Nucleic acid-based methods for the detection of cancer. Science 278:1054-1058, 1997
117. Roth JA, Nguyen D, Lawrence DD, et al: Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat Med 2:985-975, 1996
118. Bischoff JR, Kim DH, Williams A, et al: An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274:373-376, 1996
119. Kastan MB, Zhan Q, El-Deiry WS, et al: A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 71:587-597, 1992
120. Siliciano JD, Canman CE, Taya Y, et al: DNA damage induces phosphorylation of the amino terminus of p53. Genes Dev 11:3471-3481, 1997
121. Haupt Y, Maya R, Kazaz A, et al: Mdm2 promotes the rapid degradation of p53. Nature 387:296-299, 1997
122. Kubbutat MHG, Jones SN, Vousden KH: Regulation of p53 stability by Mdm2. Nature 387:299-303, 1997
123. Matsushime H, Ewen ME, Strom DK, et al: Identification and properties of an atypical catalytic subunit (p34 PSKJ3 /CDK4) for mammalian D-type G1 cyclins. Cell 71:323-334, 1992
124. Peeper DS, Upton TM, Ladha MH, et al: Ras signalling linked to the cell-cycle machinery by the retinoblastoma protein. Nature 386:177-181, 1997
125. Kato J, Matsushime H, Hiebert SW, et al: Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4. Genes Dev 7:331-342, 1993
126. Flemington EK, Speck SH, Kaelin WG Jr: E2F-1-mediated transactivation is inhibited by complex formation with the retinoblastoma susceptibility gene product. Proc Natl Acad Sci USA 90:6914-6918, 1993
127. Weintraub SJ, Chow KNB, Luo RX, et al: Mechanism of active transcriptional repression by the retinoblastoma protein. Nature 375:812-815, 1995
128. Smith ML, Chen I, Bae I, et al: Interaction of the p53-regulated protein gadd45 with proliferating cell nuclear antigen. Science 266:1376-1380, 1994
129. Okamoto K, Beach D: Cyclin G is a transcriptional target of the p53 tumor suppressor protein. EMBO J 13:4816-4822, 1994